Protection assessments indicated that gastrointestinal adverse situations, principally nausea and diarrhea, have been dose-dependent but usually delicate and transient. These findings set up the therapeutic window and knowledgeable dose assortment for subsequent Phase 3 trials.Renal security has been in the same way reassuring. Throughout Stage 1�